Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Change in Accured Expenses: 2018-2024

Historic Change in Accured Expenses for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Dec 2024 value amounting to $5.9 million.

  • Arcturus Therapeutics Holdings' Change in Accured Expenses fell 66.37% to -$5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.2 million, marking a year-over-year decrease of 691.77%. This contributed to the annual value of $5.9 million for FY2024, which is 1108.84% up from last year.
  • According to the latest figures from FY2024, Arcturus Therapeutics Holdings' Change in Accured Expenses is $5.9 million, which was up 1,108.84% from -$588,000 recorded in FY2023.
  • In the past 5 years, Arcturus Therapeutics Holdings' Change in Accured Expenses registered a high of $11.3 million during FY2020, and its lowest value of -$588,000 during FY2023.
  • Moreover, its 3-year median value for Change in Accured Expenses was $5.9 million (2024), whereas its average is $4.9 million.
  • In the last 5 years, Arcturus Therapeutics Holdings' Change in Accured Expenses tumbled by 106.23% in 2023 and then soared by 1,108.84% in 2024.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Change in Accured Expenses (Yearly) stood at $11.3 million in 2020, then plummeted by 63.48% to $4.1 million in 2021, then surged by 128.42% to $9.4 million in 2022, then tumbled by 106.23% to -$588,000 in 2023, then surged by 1,108.84% to $5.9 million in 2024.